-+ 0.00%
-+ 0.00%
-+ 0.00%

Oric Pharmaceuticals Reports 35% ORR in Enozertinib Phase 1b Trial for NSCLC with HER2 Exon 20 Mutations

Reuters·12/05/2025 06:00:24

Please log in to view news